Ginsenoside Rg1 (10 mg/kg/day i.p. for 3 months) reduced brain Aβ due to a marked inhibition of γ-secretase activity and preserved spatial learning and memory in transgenic AD mice overexpressing amyloid precursor protein (Tg mAPP) [66]. Here, APP is linked to Alzheimer disease.